Plasdone® S-630 Copovidone
 
 
 
 
 
CAVAMAX®, CAVASOL® and CAVITRON® cyclodextrins
 

Cyclodextrins are bucket-shaped oligosaccarides with a hydrophoic cavity and hydrophilic exterior. Given their molecular structure and shape, cyclodextrins function as molecular containers by entrapping guest molecules, such as active pharmaceutical ingredients (APIs), within the internal cavity.

ISP offers a range of cyclodextrins manufactured by Wacker Chemie for pharmacuetical applications.  Our alliance with Wacker combines Wacker’s manufacturing expertise and our pharmecuetical technical sales and service to provide solutions to pharmaceutical formulations.

 

Product Name

Cyclodextrin
Type

Aqueous Solubility
(g/100ml water @ 25°C)

Compendial Name

Monograph Compliance

USP/NF

Ph. Eur

Japan

Native

CAVAMAX W6 Pharma

Alpha

13

Alfadex

check

check(JPE)

CAVAMAX W7 Pharma

Beta

1.7

Betadex

check

check(JPE)

CAVAMAX W8 Pharma

Gamma

23

Gamma Cyclodextrin

check

In process

n/a

Derivatives

CAVASOL W7 HP Pharma

Hydroxy propyl- beta

158

Hydroxypropyl betadex

check

check

n/a

CAVITRON W7 HP5 Pharma

Hydroxy propyl- beta

158

Hydroxypropyl betadex

check

check

n/a

CAVITRON W7 HP7 Pharma

Hydroxy propyl- beta

239

Hydroxypropyl betadex

check

check

n/a

n/a= not applicable

The CAVITRON grades of hydroxypropyl- β-Cyclodextrin are manufactured to minimize endotoxin levels and are considered acceptable for use in parenteral applications.  The CAVITRON grades of hydroxypropyl- β-Cyclodextrin differ by degree of substitution or average number of hydroxypropyl groups per each cyclodextrin molecule:

Product

Typical Degree of Substitution

Molecular Substitution

CAVASOL W7 HP Pharma

4.1-5.1

0.58-0.73

CAVITRON W7 HP5 Pharma

4.1-5.1

0.59-0.73

CAVITRON W7 HP7 Pharma

6.0-8.0

0.86-1.14

Download CAVAMAX, CAVITRON and CAVASOL Product Overview.

CAVAMAX® and CAVASOL® are registered trademarks of Wacker Chemie AG.

Benefits and applications
  • Enhances bioavailability by increasing water solubility of poorly-soluble drug actives

  • Improves the light, thermal and oxidative stability of drug actives through formation of inclusion complexes

  • Reduces dermal, gastrointestinal or ocular irritation through complex formation

  • Masks unpleasant tastes and odors of drug actives to improve patient compliance

  • Prevents dug-drug and drug additive interactions

  • Simplifies product handling by reducing volatility of actives or converting liquids to powders.